Key Concepts: Economics of vaccine production

(If you're not yet a fan, join us now by clicking the Like button)

It is difficult to understand why financing for immunization in low and lower middle income countries remains a challenge, when it is largely accepted that immunization is among one of the “best buys” for the health sector, and that its financing is primarily a national public responsibility.

Equally, the international community recognizes that immunization is a global public good in that it provides global health benefits. With the inception of the Global Alliance for Vaccines and Immunization (GAVI), the International Finance Facility for Immunization (IFFim), the global effort to reduce infant mortality – a key objective of the forth Millennium Development Goals (MDG) and the Global Immunization Vision and Strategy (GIVS) – the global context for immunization is considered favourable.
Be this as it may, in recent years, the issues involved in vaccine and immunization financing have broadened due to a number of factors particularly linked to the acceleration of new and more expensive vaccines being available for introduction in low and lower middle income countries. For the World Health Organization (WHO) and its partners, a key challenge for 2015 will be to reduce the financial barriers to facilitate the accelerated introduction of new life saving vaccines in countries, and to strengthen the capacity of national governments to engage in comprehensive planning for their programmes and to make well-informed choices about vaccines they can finance and afford within their health systems.

Click here

World Health Organization & GAVI

Comments are closed.